Veteran payments and BFSI leader to drive growth across India and support cross-regional expansion into MENA, APAC, and Africa
MUMBAI, India , May 6, 2026 /PRNewswire/ — Montran, a global provider of payment and capital market infrastructure solutions with operations in over 90 countries, has appointed P. Ramasubramani (Ram) as Chief Commercial Officer (CCO) for India.
Ram brings over two decades of experience across payments technology, financial services, and the broader BFSI sector. His appointment strengthens Montran’s leadership in one of the world’s fastest-moving payments markets.
“Ram’s appointment signals where we’re heading in India,” said Julie Esca, Montran India CEO. “He understands this market, he knows our clients, and he brings the commercial instincts we need as we move into our next phase of growth. India remains one of our most strategic markets globally, and Ram is the right leader for this moment.”
In addition to driving expansion in India, Ram will work closely with Montran’s global teams across MENA, APAC, and Africa — connecting regional opportunities and strengthening Montran’s ability to deliver across corridors.
“India’s payments infrastructure has transformed faster than almost any market in the world, and the pace is accelerating — from UPI’s scale to cross-border modernization to CBDC development,” said P. Ramasubramani, Chief Commercial Officer, Montran India. “Montran has the global depth and the local relationships to play a meaningful role in what comes next. I’m looking forward to building on that.”
About Montran
Montran is the leading provider of Payment and Capital Market Infrastructure solutions, servicing the world’s foremost financial institutions with mission-critical installations and operations in over 90 countries. Discover more at www.montran.com.
View original content:https://www.prnewswire.com/in/news-releases/montran-appoints-p-ramasubramani-as-chief-commercial-officer-for-india-302764388.html
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the…
QINGDAO, China, May 28, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) has been named the…
This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which…
Strategic partnership to deliver a structured, scalable onboarding and experience for Spire clientsNEW YORK, May…
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, May 28, 2026…
Eightco treasury composition as of May 27, 2026: $90M OpenAI equity (indirect), $18M Beast Industries…